Photo from wikipedia
Low molecular weight heparin (LMWH) is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (cVTE). Study objectives were to compare the efficacy and safety of rivaroxaban and enoxaparin in cVTE. Click to show full abstract
Low molecular weight heparin (LMWH) is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (cVTE). Study objectives were to compare the efficacy and safety of rivaroxaban and enoxaparin in cVTE.
Keywords:
safety rivaroxaban;
efficacy safety;
associated venous;
venous thromboembolism;
treatment cancer;
cancer associated
Journal Title: European Journal of Haematology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Haematology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!